Amcor stock falls after Raymond James reiterates Market Perform rating
Kenneth A. Stauderman, Chief Scientific Officer of CalciMedica, Inc. (NASDAQ:CALC), recently purchased 1,000 shares of common stock. The transaction, which occurred on July 1, 2025, involved the acquisition of shares at a price of $1.85, totaling $1,850. The purchase comes as CALC shares have shown recent momentum, gaining over 10% in the past week, though still trading significantly below analyst targets ranging from $13 to $20.
Following the transaction, Stauderman directly holds 11,944 shares of CalciMedica, Inc. The filing also indicates that Stauderman indirectly owns 1,000 shares through a spouse. InvestingPro analysis reveals additional insights about CALC’s financial health and market position, with 8 key investment tips available for subscribers.
In other recent news, CalciMedica Inc. has announced the design of its Phase 2 KOURAGE trial for Auxora, targeting acute kidney injury (AKI) with respiratory failure. The trial is set to enroll approximately 150 patients and aims to assess the efficacy of Auxora in increasing days alive without ventilator or dialysis support. This comes after promising preclinical data and a post-hoc analysis from the CARDEA trial, which showed a significant reduction in mortality among COVID-19 patients with AKI. Additionally, CalciMedica has appointed Baker Tilly US, LLP as its new independent registered public accounting firm following a merger with Moss Adams LLP. The change was approved by the company’s Board of Directors’ Audit Committee, and there were no disagreements with Moss Adams regarding accounting practices. CalciMedica has not consulted with Baker Tilly on accounting principles prior to the merger. The company has ensured transparency by including a letter from Moss Adams in its SEC filing, confirming agreement with the statements made. These developments reflect CalciMedica’s ongoing efforts in both clinical trials and corporate governance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.